The group II metabotropic glutamate receptor agonist (-)-2-oxa-4-aminobicyclo[3.1.0.]hexane-4,6-dicarboxylate (LY379268) and clozapine reverse phencyclidine-induced behaviors in monoamine-depleted rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 3, 2002, Pages 919-927

  Swanson, Chad J ^a   Schoepp, Darryle D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; CLOZAPINE; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; DOPAMINE; HALOPERIDOL; KETANSERIN; METABOTROPIC RECEPTOR AGONIST; METIROSINE METHYL ESTER; NEUROLEPTIC AGENT; NORADRENALIN; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BRAIN TISSUE; CONTROLLED STUDY; DRUG EFFECT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

AMINO ACIDS; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CATECHOLAMINES; CLOZAPINE; INJECTIONS, SUBCUTANEOUS; MALE; MOTOR ACTIVITY; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; SEROTONIN;

EID: 0036894693     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.038422     Document Type: Article

References (45)

1. Aghajanian GK and Marek GJ (2000) Serotonin model of schizophrenia: Emerging role of glutamate mechanisms. Brain Res Rev 31:302-312.
2. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP, Potkin SG, Sandman CA, Bunney WE Jr, and Jones EG (1996) Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 16:19-30.
3. Anwyl R (1999) Metabotropic glutamate receptors: Electrophysiological properties and role in plasticity. Br Res Rev 29:83-120.
4. Anis NA, Berry SC, Burton NR, and Lodge D (1983) The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 79:565-575.
5. Brunello N, Masotto C, Staeardo L, Markstein R, and Racagni G (1995) New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13:177-213.
6. Carlsson A (1995) The dopamine theory revisited, in Psychopharmacology: The Fourth Generation of Progress (Bloom FE and Kupfer DJ eds) pp 379-400, Raven Press, New York.
7. Carlsson M and Carlsson A (1989) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75:221-226.
8. Cartmell J, Monn JA, and Schoepp DD (1999) The metabotropic glutamate receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus damphetamine motor behaviors in rats. J Pharmacol Exp Ther 291:161-170.
9. Cartmell J, Monn JA, and Schoepp DD (2000) Tolerance to the motor impairment, but not the reversal of PCP-induced motor activities by oral administration of the mGlu 2/3 receptor agonist, LY379263. Naunyn-Schmiedeberg's Arch Pharmacol 361:39-46.
10. Cartmell J, Perry KW, Salhoff CR, Monn JA, and Schoepp DD (2001) Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated and can be elicited in the presence of uptake blockade. Neuropharmacology 40:847-855.
11. Cartmell J, Salhoff CR, Perry KW, Monn JA, and Schoepp DD (2000) Dopamine and 5-HT turnover are increased by the mGlu2/3 receptor agonist LY379268 in rat medial prefrontal cortex, nucleus accumbens and striatum. Brain Res 887:378-384.
12. Cartmell J and Schoepp DD (2000) Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 75:889-907.
13. Chavez-Noriega LE, Scaffhauser H, and Campbell UC (2002) Metabotropic glutamate receptors: Potential drug targets for the treatment of schizophrenia. Curr Drug Targets 1:261-281.
14. Clark M, Johnson BG, Wright RA, Monn JA, and Schoepp DD (2002) Effects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine-sensitized rats. Pharmacol Biochem Behav 73:339-346.
15. Creese I, Burt DR, and Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science (Wash DC) 192:481-483.
16. Forsythe ID and Barnes-Davies M (1997) Synaptic transmission: Well placed modulators. Curr Biol 7:R362-R365.
17. Halberstadt AL (1995) The phencyclidine-glutamate model of schizophrenia. Clin Neuropharmacol 18:237-249.
18. Javitt JD and Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
19. Krebs-Thomson K, Lehmann-Masten V, Naiem S, Paulus MP, and Geyer MA (1998) Modulation of phencyclidine-induced changes in locomotor activity and patterns in rats by serotonin. Eur J Pharmacol 343:135-143.
20. Martin P, Carlsson ML, and Hjorth S (1998) Systemic PCP treatment elevates brain extracellular 5-HT: A microdialysis study in awake rats. Neuroreport 9:2985-2988.
21. 2A receptors. Eur J Pharmacol 280:R9-R11.
22. 2A and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther 292:76-87.
23. 2A sites for PCP-induced locomotion in the rat. Eur J Neurosci 11:4419-4432.
24. Moghaddam B and Adams BW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science (Wash DC) 281:1349-1352.
25. Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, Howe T, Alt CA, Rhodes GA, Robey RL, et al. (1997) Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): A potent, selective and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 40:528-537.
26. Murray TF and Horita A (1979) Phencyclidine-induced stereotyped behavior in rats: Dose response effects and antagonism by neuroleptics. Life Sci 24:2217-2225.
27. Nakanishi S (1992) Molecular diversity of glutamate receptors and implications for brain function. Science (Wash DC) 258:597-603.
28. Ohishi H, Shigemoto R, Kaneko T, Nakanishi S, and Mizuno N (1993a) Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience 53:1009-1018.
29. Ohishi H, Shigemoto R, Kaneko T, Nakanishi S, and Mizuno N (1993b) Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: An in situ hybridization study. J Comp Neurol 335:252-266.
30. Ohishi H, Ogawa-Meguro R, Shigemoto R, Kaneko T, Nakanishi S, and Mizuno N (1994) Immunohistochemical localization of metabotropic glutamate receptors, mGluR2 and mGluR3, in rat cerebellar cortex. Neuron 13:55-66.
31. Olney JW, and Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007.
32. Ornstein PL, Arnold MB, Augenstein NK, Lodge D, Leander JD, and Schoepp DD (1993) 3SR,4aRS,6RS,8aRS-6-(2-(1H-tetrazol-5-yl)ethyl)-decahydroisoquinoline- 3-carboxylic acid: A structurally novel, systemically active, competitive AMPA receptor antagonist. J Med Chem 36:2046-2048.
33. Ottersen OP and Landsend AS (1997) Organization of glutamate receptors at the synapse. Eur J Neurosci 9:2219-2224.
34. Phillips M, Wang C, and Johnson K (2001) Pharmacology characterization of locomotor sensitization induced by chronic phencyclidine administration. J Pharmacol Exp Ther 296:905-913.
35. Pin J-P and Duvoisin R (1995) The metabotropic glutamate receptors: Structure and functions. Neuropharmacology 34:1-26.
36. Schoepp DD (2001) Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 299:1-9.
37. Schoepp DD, Cartmell J, Johnson BG, Salhoff CR, Wright RA, Tizzano JP, and Monn JA (2001) Metabotropic glutamate receptors: A novel approach to treat psychiatric disease, in Excitatory Amino Acids: Ten Years Later (Turski L, Schoepp DD, and Cavalheiro EA eds) pp 207-216, IOS Press, Burke, VA
38. Schoepp DD, Lodge D, Bleakman D, Leander JD, Tizzano JP, Wright RA, Palmer AJ, Salhoff CR, and Ornstein PL (1995) In vitro and in vivo antagonism of AMPA receptor activation by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyll decahydroisoquinoline-3-carboxylic acid. Neuropharmacology 34:1159-1168.
39. Schoepp DD and Marek GJ (2002) Preclinical pharmacology of mGlu2/3 receptor agonists: Novel agents for schizphrenia? Curr Drug Targets 1:215-225.
40. Schreiber R, Lowe D, Voerste A, and De Vry J (2000) LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine. Eur J Pharmacol 388:R3-R4.
41. Seeman P (1995) Dopamine receptors: clinical correlates, in Psychopharmacology: The Fourth Generation of Progress (Bloom FE and Kupfer DJ eds) pp 295-302, Raven Press, New York.
42. Seeman P, Lee T, Chau-Wong M, and Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature (Lond) 261:717-719.
43. Steinpreis RE (1996) The behavioral and neurochemical effects of phencyclidine in humans and animals: Some implications for modeling psychosis. Behav Brain Res 74:45-55.
44. Sturgeon RD, Fessler RG, and Meltzer HY (1979) Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats. Eur J Pharmacol 59:169-179.
45. Zhang W and Bymaster FP (2000) In vivo receptor neurochemical studies with olanzapine, in Olanzapine (Zyprexa): A Novel Antipsychotic (Tran PV, Bymaster FP, Tye N, Herrera JM, Breier A, and Tollefson GD eds) pp 146-159, Lippincott Williams & Wilkins, Philadelphia.